143 related articles for article (PubMed ID: 35604960)
1. Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial.
Bäcklund M; Eriksson M; Gabrielson M; Hammarström M; Quay S; Bergqvist J; Hellgren R; Czene K; Hall P
Oncologist; 2022 Jul; 27(7):e597-e600. PubMed ID: 35604960
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
[TBL] [Abstract][Full Text] [Related]
3. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
[TBL] [Abstract][Full Text] [Related]
4. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer.
Braal CL; Jager A; Hoop EO; Westenberg JD; Lommen KMWT; de Bruijn P; Vastbinder MB; van Rossum-Schornagel QC; Thijs-Visser MF; van Alphen RJ; Struik LEM; Zuetenhorst HJM; Mathijssen RHJ; Koolen SLW
Clin Pharmacokinet; 2022 Apr; 61(4):527-537. PubMed ID: 34786650
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.
Skaar TC; Desta Z
Clin Pharmacol Ther; 2018 May; 103(5):755-757. PubMed ID: 29473149
[TBL] [Abstract][Full Text] [Related]
8. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
Martinez de Dueñas E; Ochoa Aranda E; Blancas Lopez-Barajas I; Ferrer Magdalena T; Bandrés Moya F; Chicharro García LM; Gómez Capilla JA; Zafra Ceres M; de Haro T; Romero Llorens R; Ferrer Albiach C; Ferriols Lisart R; Chover Lara D; López Rodríguez A; Munárriz Ferrandis J; Olmos Antón S
Breast; 2014 Aug; 23(4):400-6. PubMed ID: 24685597
[TBL] [Abstract][Full Text] [Related]
9. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.
Thorén L; Lindh JD; Ackehed G; Kringen MK; Hall P; Bergh J; Molden E; Margolin S; Eliasson E
Br J Clin Pharmacol; 2021 Mar; 87(3):1243-1252. PubMed ID: 32713032
[TBL] [Abstract][Full Text] [Related]
10. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?
Lee CI; Fox P; Balakrishnar B; Balleine RL; Gao B; Provan P; Coulter S; Liddle C; Hui R; Wong M; Gurney H; Wilcken N
Breast; 2019 Aug; 46():52-57. PubMed ID: 31082762
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22.
Baxter SD; Teft WA; Choi YH; Winquist E; Kim RB
Breast Cancer Res Treat; 2014 Jun; 145(2):419-28. PubMed ID: 24744093
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
[TBL] [Abstract][Full Text] [Related]
14. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.
Maximov PY; McDaniel RE; Fernandes DJ; Korostyshevskiy VR; Bhatta P; Mürdter TE; Flockhart DA; Jordan VC
Br J Pharmacol; 2014 Dec; 171(24):5624-35. PubMed ID: 25073551
[TBL] [Abstract][Full Text] [Related]
15. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
[TBL] [Abstract][Full Text] [Related]
16. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
[TBL] [Abstract][Full Text] [Related]
17. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
[TBL] [Abstract][Full Text] [Related]
18. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism.
Koubek EJ; Buhrow SA; Safgren SL; Jia L; Goetz MP; Ames MM; Reid JM
Drug Metab Dispos; 2023 Feb; 51(2):183-192. PubMed ID: 36351835
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
